D.E. Shaw & Co’s AgomAb Therapeutics NV AGMB Stock Holding History

D.E. Shaw & Co’s Portfolio AGMB Stock Details AGMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,326	Closed	-$161K	–	5347
2026 Q1	$161K	Buy	+15,326	New	+$217K	﹤0.01%	4233

Other funds holding AGMB

EFM

EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

Andera Partners Paris $206M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

D.E. Shaw & Co's AGMB Position: Q2 2026 in Review

D.E. Shaw & Co sold out of AgomAb Therapeutics NV (AGMB) in Q2 2026, closing a stake of 15,326 shares — an estimated $161K sold.

D.E. Shaw & Co first reported a position in AGMB in Q1 2026 and held it in 1 quarter. The position peaked at $161K in Q1 2026. 34 funds tracked by Wall St. Rank hold AGMB as of Q2 2026.

D.E. Shaw & Co reported no remaining AgomAb Therapeutics NV position as of Q2 2026 after selling out during the quarter.
D.E. Shaw & Co sold 15,326 AgomAb Therapeutics NV shares in Q2 2026, an estimated $161K.
D.E. Shaw & Co first reported a position in AgomAb Therapeutics NV in Q1 2026 and held it in 1 quarter.
D.E. Shaw & Co's AgomAb Therapeutics NV position peaked at $161K in Q1 2026.
34 funds tracked by Wall St. Rank held AgomAb Therapeutics NV as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.